Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Chhabra
Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Early Stage Cervical Cancer, Therapy for Reproductive Health and Quality Survival
Open Medicine Journal
Related publications
A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies
Cancer
Cancer Research
Oncology
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
Ono-4059 (Gs-4059), a Next Generation BTK Inhibitor, Monotherapy in Patients With B-Cell Malignancies in the Japanese Phase 1, Dose-Escalation Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 1 Trials of Anti-Enpp3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Clinical Cancer Research
Cancer Research
Oncology
Safety and Pharmacokinetics of MM-302, a HER2-targeted Antibody–liposomal Doxorubicin Conjugate, in Patients With Advanced HER2-positive Breast Cancer: A Phase 1 Dose-Escalation Study
British Journal of Cancer
Cancer Research
Oncology
Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
British Journal of Haematology
Hematology
P1.01-37 BPI-9016M, a Novel C-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results From a First-In-Human, Phase 1, Dose-Escalation Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology